Findings

What do systematic reviews say?

2 questions · 5 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 40%High 3 · 60%

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.73 [0.68, 0.79]
10 studies · 3595 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.75 [0.69, 0.82]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.64 [0.54, 0.76]
2 studies · 762 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.72 [0.66, 0.77]
10 studies · 3464 participants
High

Progression‐free survival · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.69 [0.52, 0.92]
324 participants
Moderate